Abstract Submission

3rd Annual Scientific Meeting of AHAD-AP
15 & 16 September 2023
Bangkok, Thailand

Co-Hosted by: Pediatric Hematology & Oncology Division, Chulalongkorn University In collaboration with Thai Society of Hematology

Session Date: September 16, 2023

Timing for session: 11:15 AM - 12:25 PM ICT

ORAL PRESENTATION
HALL A	Abstract ID	Abstract Title	Presenting Author	Presenting Author Affiliation
	OP-I-01 88	Role of Low Dose prophylaxis of Anti Hemophilic Factor in Hemophilia	Sudipta Nandi	Maulana Azad Medical College
	OP-I-02 108	Successful removal of high titer inhibitor in a patient with severe hemophilia A by low dose rituximab combined with low dose FVIII immune tolerance therapy	Li Zhou	The Second Affiliated Hospital of Anhui Medical University
	OP-I-03 71	Barriers to cascade screening and prenatal testing in families with inherited bleeding disorders.	Archit Sunil Pandharipande	Post Graduate Institute of Child Health Noida
	OP-I-04 96	Managing surgical procedures in children with inherited bleeding disorders; a single center experience	Eby P Baby	PGICH, Noida
	OP-I-05 90	Management of severe hemophilia with inhibitors to factor VIII with recurrent retroperitoneal bleed.	Vijayshree Muthukumar	Apollo Hospital
	OP-I-06 84	Validation test for Hemophilia self screening tool In South Kalimantan, Indonesia	Wulandewi Marhaeni	HTC Ulin General hospital / Universitas Lambung Mangkurat
HALL B	OP-II-01 73	Effectiveness of Myofascial therapy (MFT) and Conventional physiotherapy (CPT) with intermittent prophylaxis on Joint Health in Haemophilic Arthropathy- A Proof of Concept Randomized Control Trial	Diksha Sarwan	Christian Medical College and Hospital
	OP-II-02 76	Estimated cost per bleed saved: On-Demand (OD) versus Low-dose Prophylaxis (LDP) for Indonesian children with Severe Hemophilia A (SHA)	Christina Hill-Zabala	Grifols Asia Pacific
	OP-II-03 97	Out-of-pocket expenditure incurred during treatment of Hemophilia at a government facility in North India	Manju Singh	PGICH
	OP-II-04 104	Burden of Care and Quality of Life Among Caregivers of Filipino Children with Hemophilia Before and During the COVID-19 Pandemic: A Cross-Sectional Study	Noah Sacluti	University of Santo Tomas Hospital
	OP-II-05 135	REHABILITATION FOR THE IMPROVEMENT OF FUNCTIONAL STATUS IN HEMOPHILIACS	Sudipta Nandi	Maulana Azad Medical College
	OP-II-06 74	Sufferings beyond the Physical impact of Haemophilia- A mixed method study on personal, social, economic domains and its association with quality of life in patients with haemophilia (PWH) and their caregivers (WE CARE)	Shivani Bhanwra	CMC Ludhiana

Session Date: September 15, 2023

Timing for session: 16:30 – 17:00 PM ICT

POSTER PRESENTATION
COMPREHENSIVE CARE	Abstract ID	Abstract Title	Presenting Author	Presenting Author Affiliation
	PP-01 78	Health-Related Quality of Life of Adult Filipinos with Hemophilia in the Philippines	Ma. Angelina L. Mirasol	OLLH
	PP-02 82	A comparative analysis of the quality-of-life in children with Rare Bleeding Disorders using Haemo-QOL	Manju Singh	PGICH
	PP-03 83	Pros and Cons of the Hemophilia Hotline Telephone Consult Service	Kamala Laohverapanich	Ramathibodi hospital
	PP-04 99	Management of Haemophilia in Developing Countries with geographic variation: Experience from Nepal.	Niraj Kumar Singh	NAMS, Bir Hospital
LABORATORY	PP-05 42	Utility of Kaolin TEG and Rapid TEG to predict Coagulopathy in Severe Traumatic Brain Injury	Tushar Sehgal	AIIMS DELHI
	PP-06 72	Comparative Analysis Between Inhibitor Screen and Mini-Bethesda Assay to Diagnose Low Titer Inhibitors in Hemophilia A Patients- An Experience from an HTC in India	Madhura Deshpande	Bharati Vidyapeeth Medical College and Hospital
	PP-07 129	Low titer of F VIII inhibitor in children with hemophilia A: a single centre experience in Indonesia	Resna Nurhantika Sary	University of Indonesia
MUSCULOSKELETAL	PP-08 107	Effect of Proprioceptive Training on Physical Mobility and Quality of Life of Persons with Hemophilia on On-Demand Therapy from South India - A Case Series	Uday Raj Devaraju Juttuka	Little Stars and She, Women and Children Hospital
MUSCULOSKELETAL	PP-09 127	Impact of emicizumab prophylaxis on health-related quality of life and musculoskeletal outcomes: a real-world experience from Indonesia	Dina Clarisa Rumora Abigail	Universitas Indonesia
MEDICAL	PP-10 44	A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients	Munirah Jamal	National Pharmaceutical Regulatory Agency
PP-11 69	Ruptured Chronic Hemophilic Pseudotumor in a 48 Male with High Titer Inhibitor: A Case Report on Outcome and Lessons Learned	Ma. Angelina L. Mirasol	OLLH
PP-12 70	Management of Pseudotumors in Persons with Hemophilia: A Case Series	Nattawan Arkarattanakul	faculty of medicine, Chiangmai unversity
PP-13 77	Unmasking Hemophilia C in bleeding elderly filipinos post trauma: presentation and management outcomes	Ma. Angelina L. Mirasol	OLLH
PP-14 79	Anemia and Iron Profile in Children with Hemophilia A	Andi Cahyadi	Dr. Soetomo General Academic Hospital
PP-15 85	Extended half-life clotting factors in management of Hemophilia – a single center experience .	Archit Sunil Pandharipande	Post Graduate Institute of Child Health Noida
PP-16 86	Characteristics of Hemophilia Patients with Hematuria at Children’s Hospital No 1.	Tin Ngoc Nguyen	Children's hospital No 1
PP-17 87	Hemophilic Pseudotumor of Abdomen	Anshul Tomar	Maulana Azad Medical College
PP-18 89	Acquired Hemophilia A in A Beta Thalassemia Girl, Presenting with Salter-Harris Fracture of Bilateral Knee: Case Report	Wulandewi Marhaeni	HTC Ulin General hospital / Universitas Lambung Mangkurat
PP-19 91	Case series of low dose monthly Emicizumab prophylaxis in von Willebrand disease Type III	Vijayshree Muthukumar	Apollo Hospital
PP-20 92	Subgaleal hemorrhage in hemophilia; a case series	Eby P Baby	PGICH, Noida
PP-21 93	A Rare Case of Splenic Hemangioma Resulting in Kasabach Merritt Syndrome	Anupama Nair	Apollo Cancer Centre, Chennai
PP-22 94	Outcomes of Hematopoietic Stem Cell Transplantation In Inherited Bleeding Disorders In A Tertiary Care Center	Anupama Nair	Apollo Cancer Centre, Chennai
PP-23 95	Spontaneous spinal epidural hematoma in children with hemophilia – case series	Eby P Baby	PGICH, Noida
PP-24 98	Intracranial Haemorrhage in Paediatric Haemophilia Patients – the KK Women’s and Children’s Hospital Experience	Sarah Chong	KK Women’s and Children’s Hospital
PP-25 113	Outcomes of Available Treatment Modalities of Adult Filipino Hemophilia Patients at a Tertiary Hospital in the Philippines: A 5-Year Retrospective Analysis	Ma. Angelina L. Mirasol	OLLH
PP-26 114	Clinical profile of patients undergoing thromboelastography and its effectiveness as a point of care diagnostic modality in hemostasis	Tejaswini Gudibande	Mazumdar Shaw Medical Centre, Narayana Health
PP-27 125	Efficacy and safety of emicizumab for the treatment of children with hemophilia A : a systematic review	Dina Clarisa Rumora Abigail	Universitas Indonesia
PP-28 128	Clinical Characteristics of Hemophilia A Patients with Inhibitor of FVIII in A Referral Hospital in Indonesia	Sheila Claudhea Salsabila	Universitas Indonesia
PP-29 130	Characteristics of Pediatric Hemophilia Patients in Kalimantan, Indonesia	Meitria Syahadatina Noor	Faculty of Medicine, Lambung Mangkurat University
PP-30 131	Neonatal Hemophilia B with Intracranial Hemorrhage	Aye Aye Khaing	University of Medicine I
PP-31 132	Infant Hemophilia B with Intracranial Hemorrhage	Aye Aye Khaing	University of Medicine I
PP-32 134	Hepatitis C infection and HIV infection in Indonesian hemophiliac children: single-center study in Kalimantan, Indonesia	Ratih Kumala Sari	Ulin general hospital
PP-33 138	Case report Perioperative management of a patient with acquired von Willebrand syndrome in Wilms tumor	Chonlatis Srichumpuang	King Chulalongkorn Memorial Hospital

Call for Abstract

AHAD-AP envisions fostering scientific advancement in the field of haemophilia and other bleeding disorders in the Asia Pacific region. Delegates who would like to present their work at the meeting, are invited to submit an abstract for consideration by the Abstract Review Committee.

Abstract Review Committee diversity_1

Dr. M Joseph John (Co-Chair), Ludhiana, Christian Medical College Ludhiana
Dr. Patcharee Kamwilaisak (Co-Chair), Khon Kaen, Khon Kaen University
Dr. Judy Ann David, Vellore, Christian Medical College Vellore
Dr. Rattapan Lamool, Bangkok, Phramongkutklao Hospital
Dr. Tien Sim Leng, Singapore, Singapore General Hospital
Dr. Rungrote Natesirinilkul, Chiang Mai, Chiang Mai University
Dr. Anjalin D’Souza (PhD), Manipal, Manipal Academy of Higher Education

Important Dates for Abstract Submissions table_chart

Last date for abstract submission:	14 August 2023
Notification of acceptance for oral/poster presentations:	21 August 2023
Last date for withdrawal of oral or poster presentation:	4 September 2023

Please carefully read the following guidelines and sample abstract prior to submitting an abstract online.

General Guidelines

You are invited to submit informative abstracts of up to 300 words, which would not include the title of the abstract and author affiliations and other headings like Aims, Methods, Results & Conclusions. The abstract may include a maximum of two non-text items (Tables/Graphs) (which will not be included in the 300-350 words limit.
Abstracts must describe original work at the time of the submission. Case Reports/Case Series are also encouraged.
All abstracts are subject to review by the Abstract Review Committee and acceptance into the program is not guaranteed.
The Abstract Review Committee will review each abstract and the best 12 abstracts (6 abstracts Physician and Lab and 6 abstracts- MSK and Nursing) will be invited to present as oral presentation during the meeting. (7mins + 3 mins discussion for each)
Abstracts must be submitted online via the official abstract submission website.
Encore abstracts allowed with 'original' data presented at recent major international meetings.

Abstracts must be submitted according to guidelines given below:

Abstract Title

Please write the title in Sentence Case. Do not use quotation marks.

(Example: The Results of the Research Case Study and Its Participants)

Authors and Affiliations

The full names (no initials) of all participating authors (including yourself) must be included on the abstract. Please do not include degrees or professional titles. Author Affiliations – please include the name of your organization, the city, the state, and the country.

Abstract Text

The Committee suggests that the abstract follow the format outlined below.

Aims
Methods
Results
Conclusions
Key words: 3-5 words

Case Reports/Case Series are also encouraged.

Conflict of Interest Statement

If the research described in the abstract was supported by a commercial company, you must indicate the company's role in analysing the data or preparing the abstract.

One of the following must appear at the bottom of the abstract:

"No conflict of interest to disclose".

"This research was supported by __________. The company had no role in analysing the data or preparing the abstract."

"This research was supported by __________. The company inserts free text describing the company's role in data analysis or abstract preparation."

This conflict-of-interest statement is mandatory for all abstracts submitted and will appear wherever the abstracts are published. For oral presentations, a sample slide will be available to presenters for disclosure of conflicts of interest to be displayed as the first or second slide of their presentation.

Abstracts are accepted on a wide range of topics in haemophilia and bleeding disorders

Available topics are:

Haemophilia and Bleeding disorders. The submitters can select the right topic for each abstract submitted.

Medical
Laboratory
Musculoskeletal
Comprehensive Care: Nursing, Dental, Psychosocial

Submission of the abstract carries with it an obligation to present the accepted abstract in person without any change in scientific content during the allotted time in the above conference.

The abstracts would be judged on the following parameters by the independent experts.

Significance of the topic
Clarity of Objectives
Methodological rigor & Scientific quality
Originality
Relevance

Withdrawal of presentation should be intimated to the Abstract Review Committee on or before 20 August 2023.

If the abstract is not submitted in the prescribed format, it will not be considered for review.

The final decision of the abstract committee will be binding.

More than 1 abstract can be submitted by any individual/ author.

Abstract submission is closed